▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
MYS 014
Consider Mysimba for patients who eat in response to their emotions or have difficulty managing their cravings1*
A systematic review of 18 studies (n=21,237) suggests 44.9% of people may be emotional eaters2
- #Treatment with Mysimba should be discontinued after sixteen weeks if patients have not lost at least 5% of their initial body weight
- *The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood
Emotional eating - a challenge for weight-loss success
When it comes to treating obesity, one size doesn’t fit all. Every patient is different, and their treatment should be too. The Acosta et al observational study found that an individualized treatment approach based on 4 obesity-related phenotypes was associated with significantly greater weight loss after 12 months compared with the non–phenotype-guided groups. For some patients, this means addressing their cravings that can be associated with emotional eating, which occurs when someone eats to cope with positive or negative emotions.1
Proven efficacy with Mysimba®3
Help your patients who are overweight or struggling with obesity achieve sustained weight loss.3,4
Completers lost an average of 11.3 kg vs 7.3 kg for placebo at 56 weeks4‡
ITT-LOCF: ~8.2 kg for Mysimba® and ~5.0 kg for placebo3‡
There was an average decrease of 11.2 cm in waist circumference for completers vs 7.7 cm for placebo5‡
ITT-LOCF: -10 cm for Mysimba® and -6.8 cm for placebo5‡
‡Difference from placebo, P<0.001.
Study design: COR-BMOD was a 56-week, multicentre, double-blind, placebo-controlled study. Patients were randomised to receive Mysimba® 32 mg/360 mg daily or placebo. The coprimary endpoints were percent change from baseline body weight and the proportion of patients achieving a ≥5% reduction in body weight at Week 56. Unless noted otherwise, data shown are from the ITT analysis, which included all randomised patients who had body-weight measurements at baseline and at least once postbaseline. LOCF was used for missing data.3,4
Patients met in groups of 10 to 20 people for 90 minutes and received intensive behavioural modification by registered dietitians, behavioural psychologists, or exercise specialists. Group meetings were held weekly for the first 16 weeks, every other week for the next 12 weeks, and monthly thereafter (28 sessions in total)4.
Mysimba® ITT:
n=565; placebo ITT: n=196. Average baseline parameters were Mysimba®: 100.2 kg, 109.2-cm waist circumference; placebo: 101.6 kg, 109.2-cm waist circumference. Patients who completed 56 weeks of treatment: Mysimba® (57.9%); placebo (58.4%).3,4
In another randomised controlled trial (COR-I) with similar average baseline parameters
to COR-BMOD, endpoint results over 56 weeks in completers/ITT-LOCF groups for patients taking
Mysimba® (n=296/538) vs placebo (n=290/536), respectively, were mean weight
change from baseline (-8.1%/-5.4% vs -1.8%/-1.3%), patients achieving ≥5% weight loss: 62%/42% vs 23%/17%;
and mean change in waist circumference: -6.9 cm/-6.2 cm vs -2.7 cm/-2.5 cm.3,4-6
COR-I=CONTRAVE Obesity Research I; COR-BMOD=COR behaviour modification; ITT=intent to treat; LOCF=last
observation carried forward.
Mysimba® targets two areas of the brain to reduce hunger and control cravings3,7§
Mysimba® is the only 2-in-1 combination drug containing prolonged-release (PR) naltrexone and bupropion that targets the brain’s appetite regulatory centre and the mesolimbic reward system.3
§The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.3
Do your patients seeking weight loss eat for comfort?
Find out more about the obstacles patients may face when trying to lose weight, and identify which of your patients may be right for Mysimba®.
References:
- Acosta A, Camilleri M, Dayyeh BA, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120
- Chew HSJ, Soong RY, Ang WHD, Ngooi JW, Park J, Yong JQYO, Goh YSS. The global prevalence of emotional eating in overweight and obese populations: A systematic review and meta-analysis. Br J Psychol. 2025 May;116(2):484-498. doi: 10.1111/bjop.12768. Epub 2025 Jan 15.
- Mysimba® SmPC available at https://www.medicines.org.uk/emc/product/2684/smpc#gref accessed April 2026
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. doi:10.1038/oby.2010.147
- Data on file (Waist Circumference). Currax Pharmaceuticals LLC. Brentwood, TN; 2019.
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4
- Glider K, et al. Food craving and weight loss: An integrated analysis of the effects of prolonged-release naltrexone/bupropion on the cravings and mood sub-scales of the Control of Eating Questionnaire. Presented at the European Obesity Summit; June 1–4, 2016; Gothenburg, Sweden. Obesity Facts. 2016;9(suppl 1):80.
Important Safety Information
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
Important Safety Information
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
MYS 014
Important Safety Information
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
MYS 014
